Blepharitis – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

According to a literature survey, The prevalence of Blepharitis may vary from 37.0% to 50.0?cording to some reports in the literature, most often affecting females over 50 years of age. Females accounted for 55% to 60% of cases, and males for 40% to 45%. Regarding the severity of the disease, more than half were diagnosed with mild blepharitis 55% to 57.8%), 40% to 42.6?ses were diagnosed with moderate, and 1.6% to 3.5% as severe.

Read More:- Blepharitis – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Comprehensive insight on patient segmentation based on age, sex, Types (anterior blepharitis & posterior blepharitis), the severity of infection (Acute & Chronic), Risk factors (Dry eye, Dermatologic conditions, Demodicosis, Rosacea, Isotretinoin, Giant papillary conjunctivitis & Others), Stages (mild, moderate & Severe) Signs & Symptoms, Clinical Manifestations, Treatment types (Antibiotics; Topical and systemic, anti-inflammatory agents and Others) has been provided into the epidemiology section of the Blepharitis and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.

In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Bausch & Lomb Incorporated, Tarsus Pharmaceuticals, Inc., Keyrus Biopharma, Nicox Ophthalmics, Inc., Sun Pharma Global FZE, AxeroVision, Inc., Merck Sharp & Dohme Corp., Alcon Research, Tissue Tech Inc., Galderma, Kala Pharmaceuticals, Inc., NovaBay Pharmaceuticals, Inc., TearScience, Inc.,

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Other Reports:-
Invasive Candidiasis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Chronic Cluster Headache (CCH) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Spinocerebellar ataxias (SCAs) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Adrenomyeloneuropathy (AMN) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Corneal Ulcer – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Blepharitis Market Forecast, Blepharitis, Blepharitis market outlook report, Blepharitis competitive landscape See Campaign: https://thelansis.com/reports/blepharitis-market-insight-report/

Contact Information:

m.berg@thelansis.com

Tags:
Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English